integratedbiotherapeutics产品代理

产品分类 > 科研试剂 > integratedbiotherapeutics产品代理

integratedbiotherapeutics产品代理

Integrated BioTherapeutics, Inc. (IBT) 是一家生物技术公司,专注于发现针对新兴传染病的新型疫苗和疗法。 IBT 的管道包括有前景的细菌和病毒感染候选产品。 IBT 的细菌计划侧重于对抗葡萄球菌感染的对策,主要是针对金黄色葡萄球菌产生的各种毒素。 IBT 的金黄色葡萄球菌疫苗现已分拆为 Integrated BioTherapeutic Vaccines,将于 2022 年进入临床。IBT 的抗病毒产品线包括独特的埃博拉和马尔堡抗体疗法、丝状病毒和尼帕病毒疫苗,以及针对新兴病毒的强大发现产品线。此外,IBT 开发了一种新的抗体工程技术,用于将抗毒素抗体靶向细菌表面,将毒素中和与效应子功能相结合。
除了 IBT 积极的抗传染病发现管道,我们还经营一项名为 IBT Bioservices 的 CRO 业务,为工业和学术客户提供最先进的传染病发现能力关键试剂以及动物模型测试服务。
IBT 位于马里兰州罗克维尔,与美国政府机构有着密切的工作关系,包括美国国家过敏症和传染病研究所 (NIAID/NIH)、国家癌症研究所 (NCI)、国防部 (DOD)、美国陆军医疗传染病研究所(USAMRIID),以及许多生物技术和制药公司和学术实验室。
价格: 0.00

Integrated   BioTherapeutics, Inc. (IBT) is a biotechnology company focused on the   discovery of novel vaccines and therapeutics for emerging infectious   diseases. IBT’s pipeline includes promising product candidates for bacterial and   viral infections. IBT’s bacterial program is focused on countermeasures against   staphylococcal infections, primarily by targeting a variety of toxins   produced by S. aureus. IBT’s S. aureus vaccine, now spun off into Integrated BioTherapeutic   Vaccines, is entering the clinic in 2022.    IBT’s antiviral pipeline includes unique Ebola and Marburg antibody therapeutics,   vaccines for filoviruses and Nipah virus, and a strong discovery pipeline for   emerging viruses. Further, IBT developed a novel antibody engineering   technology for targeting anti-toxin antibodies to the surface of bacteria,   integrating toxin neutralization with effector functions.

In addition   to the active anti-infectious disease discovery pipeline at IBT, we also   operate a CRO business called IBT Bioservices which provides state of the art   infectious disease discovery capabilities critical reagents as well as animal   model testing services to industrial and academic clients.

   

Located in Rockville, Maryland, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and many biotechnology and pharmaceutical companies and academic laboratories.